search
Back to results

Treating Chronic Insomnia in Breast Cancer Patients

Primary Purpose

Chronic Insomnia

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Placebo
Ramelteon
Sponsored by
Accelerated Community Oncology Research Network
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Insomnia focused on measuring chronic insomnia

Eligibility Criteria

21 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female patients aged 21-60 years old Have a negative serum or urine pregnancy test for women of child-bearing potential Have a three-month or longer history of insomnia Self-report < 6.5 hours of total sleep time, in addition to a sleep efficiency of less than 85%, averaged over two weeks of screening A score of less than 60 on the Zung Self-Rating Depression Scale Self-report bedtimes that do not vary by more than two hours on five nights per week Have completed chemotherapy for breast cancer less than two years prior to study drug administration Have completed chemotherapy for breast cancer for at least two months prior to screening visit Patients that are receiving Herceptin are eligible for study enrollment Have completed radiation therapy for breast cancer for at least two months prior to screening visit ECOG (Eastern Cooperative Oncology Group)score of 0-1 Be able to read, understand, and provide written informed consent before enrolling in the study Must be willing to comply with all study visits and comply with daily phone calls to the IVRS throughout the study Agree to participate for the entire study period (about two months) Exclusion Criteria: Metastatic disease Pregnant or lactating female Self-reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly Self-reports use of products containing nicotine of greater than 15 cigarettes daily or cannot avoid products containing nicotine during sleep periods Current use of any of the following medications, and cannot discontinue these medications for the duration of the study: Hypnotic medication, Anti-convulsants, Anxiolytics, Narcotic analgesics, Medications or supplements containing Melatonin, Ketaconazole and Fluconazole Currently taking fluvoxamine, brand name Luvox Have symptoms consistent with the diagnosis of any other sleep disorder other than insomnia (e.g. obstructive sleep apnea, narcolepsy, restless legs syndrome) Currently on night or rotating shift work Self-reports habitual napping of greater than one hour accumulated sleep on 4 or more days per week Has a psychiatric illness that interferes with normal sleep-wake function (e.g. major depression, post-traumatic stress disorder) A score of 60 or greater on the Zung Self-Rating Depression Scale Has current unstable medical disorder, such as symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or other serious medical condition as determined by the Investigator

Sites / Locations

  • Genesis Cancer Center
  • Wilshire Oncology Medical Group, Inc.
  • Eastern Connecticut Hematology and Oncology Associates
  • Augusta Oncology Associates, PC
  • North Idaho Cancer Center
  • Hematology Oncology Centers of the Northern Rockies
  • Tri-County Hematology & Oncology Associates
  • Pottsville Cancer Center
  • The West Clinic
  • Cancer Specialists of Tidewater, Ltd.

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

1 (Placebo)

2 (Ramelteon)

Arm Description

Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.

Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.

Outcomes

Primary Outcome Measures

Sleep Efficiency
Total time in bed is calculated as the time the subject got out of bed minus the time the subject went to bed. The total sleep time is reported by the subject. Percent sleep efficiency is calulated as 100*(total sleep time divided by total time in bed).

Secondary Outcome Measures

Quantitative Sleep Parameters - Total Sleep Time
The subject reports how many hours of sleep she got.
Quantitative Sleep Parameters - Number of Awakenings
The subject reports how many times she woke up during the night.
Qualitative Evaluation of Sleep - Global Sleep Impression
The Patient Global Impression is a 7-point scale which asks "How much has your sleep improved?" with the following anchors: no improvement, minimal improvement, slight improvement, moderate improvement, very good improvement, near complete improvement, and complete improvement.
Qualitative Evaluation of Sleep - Quality of Sleep
The subject rates the quality of her sleep on a scale of 0 through 10, where 0 is a very bad night of sleep and 10 is a very good night of sleep.
Daytime Function - Fatigue
The subject rates her fatigue on a scale of 0 through 10, where 0 is not a problem and 10 is as bad as possible.
Daytime Function - Despair
The subject rates 7 questions related to despair on a scale of 0 through 10 for each question, where 0 is not bad and 10 is as bad as possible. The scores of these 7 questions are combined and normalized, and used to describe despair.
Daytime Function - Distress
The subject rates 4 questions related to distress on a scale of 0 through 10 for each question, where 0 is not bad and 10 is as bad as possible. The scores of these 4 questions are combined and normalized, and used to describe distress.

Full Information

First Posted
June 13, 2006
Last Updated
August 18, 2011
Sponsor
Accelerated Community Oncology Research Network
Collaborators
Takeda Pharmaceuticals North America, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00337272
Brief Title
Treating Chronic Insomnia in Breast Cancer Patients
Official Title
Phase IV: Treatment of Chronic Insomnia in Patients With Breast Cancer Following Completion of Chemotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Terminated
Why Stopped
Lack of enrollment.
Study Start Date
August 2006 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
January 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Accelerated Community Oncology Research Network
Collaborators
Takeda Pharmaceuticals North America, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is being conducted to evaluate the effectiveness of ramelteon 8mgs in the treatment of insomnia in patients that have completed their first chemotherapy treatment for breast cancer.
Detailed Description
Phase IV, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ramelteon 8mgs in the treatment of insomnia in patients with breast cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Insomnia
Keywords
chronic insomnia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 (Placebo)
Arm Type
Placebo Comparator
Arm Description
Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
Arm Title
2 (Ramelteon)
Arm Type
Active Comparator
Arm Description
Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo taken 30 minutes before bedtime days 1-28 of treatment period
Intervention Type
Drug
Intervention Name(s)
Ramelteon
Other Intervention Name(s)
Rozerem
Intervention Description
8 mgs daily for days 1-28 of treatment period
Primary Outcome Measure Information:
Title
Sleep Efficiency
Description
Total time in bed is calculated as the time the subject got out of bed minus the time the subject went to bed. The total sleep time is reported by the subject. Percent sleep efficiency is calulated as 100*(total sleep time divided by total time in bed).
Time Frame
Every morning during the screening, treatment, and withdrawal periods
Secondary Outcome Measure Information:
Title
Quantitative Sleep Parameters - Total Sleep Time
Description
The subject reports how many hours of sleep she got.
Time Frame
Every morning during the screening, treatment, and withdrawal periods
Title
Quantitative Sleep Parameters - Number of Awakenings
Description
The subject reports how many times she woke up during the night.
Time Frame
Every morning during the screening, treatment, and withdrawal periods
Title
Qualitative Evaluation of Sleep - Global Sleep Impression
Description
The Patient Global Impression is a 7-point scale which asks "How much has your sleep improved?" with the following anchors: no improvement, minimal improvement, slight improvement, moderate improvement, very good improvement, near complete improvement, and complete improvement.
Time Frame
Once during the withdrawal period
Title
Qualitative Evaluation of Sleep - Quality of Sleep
Description
The subject rates the quality of her sleep on a scale of 0 through 10, where 0 is a very bad night of sleep and 10 is a very good night of sleep.
Time Frame
Every morning during the screening, treatment, and withdrawal periods
Title
Daytime Function - Fatigue
Description
The subject rates her fatigue on a scale of 0 through 10, where 0 is not a problem and 10 is as bad as possible.
Time Frame
Once during the screening period; once during the treatment period; twice during the withdrawal period for a total of 4 assessments
Title
Daytime Function - Despair
Description
The subject rates 7 questions related to despair on a scale of 0 through 10 for each question, where 0 is not bad and 10 is as bad as possible. The scores of these 7 questions are combined and normalized, and used to describe despair.
Time Frame
Once during the screening period; once during the treatment period; twice during the withdrawal period for a total of 4 assessments
Title
Daytime Function - Distress
Description
The subject rates 4 questions related to distress on a scale of 0 through 10 for each question, where 0 is not bad and 10 is as bad as possible. The scores of these 4 questions are combined and normalized, and used to describe distress.
Time Frame
Once during the screening period; once during the treatment period; twice during the withdrawal period for a total of 4 assessments

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients aged 21-60 years old Have a negative serum or urine pregnancy test for women of child-bearing potential Have a three-month or longer history of insomnia Self-report < 6.5 hours of total sleep time, in addition to a sleep efficiency of less than 85%, averaged over two weeks of screening A score of less than 60 on the Zung Self-Rating Depression Scale Self-report bedtimes that do not vary by more than two hours on five nights per week Have completed chemotherapy for breast cancer less than two years prior to study drug administration Have completed chemotherapy for breast cancer for at least two months prior to screening visit Patients that are receiving Herceptin are eligible for study enrollment Have completed radiation therapy for breast cancer for at least two months prior to screening visit ECOG (Eastern Cooperative Oncology Group)score of 0-1 Be able to read, understand, and provide written informed consent before enrolling in the study Must be willing to comply with all study visits and comply with daily phone calls to the IVRS throughout the study Agree to participate for the entire study period (about two months) Exclusion Criteria: Metastatic disease Pregnant or lactating female Self-reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly Self-reports use of products containing nicotine of greater than 15 cigarettes daily or cannot avoid products containing nicotine during sleep periods Current use of any of the following medications, and cannot discontinue these medications for the duration of the study: Hypnotic medication, Anti-convulsants, Anxiolytics, Narcotic analgesics, Medications or supplements containing Melatonin, Ketaconazole and Fluconazole Currently taking fluvoxamine, brand name Luvox Have symptoms consistent with the diagnosis of any other sleep disorder other than insomnia (e.g. obstructive sleep apnea, narcolepsy, restless legs syndrome) Currently on night or rotating shift work Self-reports habitual napping of greater than one hour accumulated sleep on 4 or more days per week Has a psychiatric illness that interferes with normal sleep-wake function (e.g. major depression, post-traumatic stress disorder) A score of 60 or greater on the Zung Self-Rating Depression Scale Has current unstable medical disorder, such as symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or other serious medical condition as determined by the Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward J. Stepanski, Ph.D.
Organizational Affiliation
Accelerated Community Oncology Research Network
Official's Role
Study Chair
Facility Information:
Facility Name
Genesis Cancer Center
City
Hot Springs
State/Province
Arkansas
ZIP/Postal Code
71913
Country
United States
Facility Name
Wilshire Oncology Medical Group, Inc.
City
La Verne
State/Province
California
ZIP/Postal Code
91750
Country
United States
Facility Name
Eastern Connecticut Hematology and Oncology Associates
City
Norwich
State/Province
Connecticut
ZIP/Postal Code
06360
Country
United States
Facility Name
Augusta Oncology Associates, PC
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30901
Country
United States
Facility Name
North Idaho Cancer Center
City
Coeur d'Alene
State/Province
Idaho
ZIP/Postal Code
83814
Country
United States
Facility Name
Hematology Oncology Centers of the Northern Rockies
City
Billings
State/Province
Montana
ZIP/Postal Code
59101
Country
United States
Facility Name
Tri-County Hematology & Oncology Associates
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Facility Name
Pottsville Cancer Center
City
Pottsville
State/Province
Pennsylvania
ZIP/Postal Code
17901
Country
United States
Facility Name
The West Clinic
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Name
Cancer Specialists of Tidewater, Ltd.
City
Chesapeake
State/Province
Virginia
ZIP/Postal Code
23320
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Treating Chronic Insomnia in Breast Cancer Patients

We'll reach out to this number within 24 hrs